Black Health Matters (BHM), the nation's leading health equity platform dedicated to improving the health outcomes of Black ...

Lepodisiran 400 mg reduced Lp(a) levels by 93.9% over 60-180 days, with sustained reductions of 74.2% at 1.5 years. No serious adverse events were linked to lepodisiran, and the Phase 3 ACCLAIM-Lp ...

In the Phase 2 ALPACA study, lepodisiran significantly reduced Lp(a) levels by an average of 93.9% over the 60 to 180-day period after treatment with the highest tested dose (400 mg), meeting the ...

The namesake WtP is maintained for consistency. Our new followup SaT provides robust, efficient and adaptable sentence segmentation across 85 languages at higher performance and less compute cost.